An observational study aimed to investigate the efficacy and side effects of vortioxetine with aripiprazole for treatment of chronic schizophrenia with MDD
Latest Information Update: 03 Dec 2021
At a glance
- Drugs Aripiprazole (Primary) ; Vortioxetine (Primary)
- Indications Major depressive disorder; Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2021 New trial record
- 05 Oct 2021 Results presented at the 34th Annual Congress of the European College of Neuropsychopharmacology